Want to track HOLX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 17 days
Summary
HOLX closed Monday higher at €55.5, an increase of 0.91% from Friday's close, completing a monthly increase of 0% or €0. Over the past 12 months, HOLX stock lost -20.71%.
HOLX is not paying dividends to its shareholders.
The last earnings report, released on Apr 30, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.34%, based on the last three reports. The next scheduled earnings report is due on Jul 28, 2025.
Hologic Inc. has completed 3 stock splits, with the recent split occurring on Apr 03, 2008.
The company's stock is traded on 11 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
HOLX Chart
Loading, please wait...
Hologic's GYN Surgical Dominance: What's Powering the Road Ahead?
HOLX's GYN Surgical arm gains momentum with Fluent Pro, global expansion and strategic acquisitions fueling growth.
Zacks | 15 hours ago
Hologic (HOLX) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, Hologic (HOLX) closed at $65.85, marking a +1.46% move from the previous day.
Zacks | 1 day ago
Is Hologic Stock's Low Valuation an Opportunity or a Value Trap?
HOLX trades below peers on P/S, but falling EPS, weak Breast Health sales and China risks cloud the outlook.
Zacks | 2 days ago
Hologic Inc. Dividends
HOLX is not paying dividends to its shareholders.
Hologic Inc. Earnings
| 28 Jul 2025 (In 2 weeks) Date | | 1.05 Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 30 Jan 2025 Date | | 1.02 Cons. EPS | 1.03 EPS |
| 7 Nov 2024 Date | | 1.02 Cons. EPS | - EPS |
| 4 Nov 2024 Date | | 1.01 Cons. EPS | 1.01 EPS |
HOLX is not paying dividends to its shareholders.
| 28 Jul 2025 (In 2 weeks) Date | | 1.05 Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 30 Jan 2025 Date | | 1.02 Cons. EPS | 1.03 EPS |
| 7 Nov 2024 Date | | 1.02 Cons. EPS | - EPS |
| 4 Nov 2024 Date | | 1.01 Cons. EPS | 1.01 EPS |
Hologic Inc. (HOLX) FAQ
What is the stock price today?
The current price is €55.50.
On which exchange is it traded?
Hologic Inc. is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is HOLX.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0%.
What is its market cap?
As of today, no market cap data is available.
What is the earnings per share?
The EPS is 1.05.
When is the next earnings date?
The next earnings report will release on Jul 28, 2025.
Has Hologic Inc. ever had a stock split?
Hologic Inc. had 3 splits and the recent split was on Apr 03, 2008.
Hologic Inc. Profile
| Medical - Instruments & Supplies Industry | Healthcare Sector | Stephen P. MacMillan CEO | XWBO Exchange | US4364401012 ISIN |
| US Country | 7,063 Employees | - Last Dividend | 3 Apr 2008 Last Split | 21 Jun 1990 IPO Date |
Overview
Hologic, Inc. is a pioneering company focused on improving women’s health through early detection and treatment, leveraging advanced diagnostics, medical imaging systems, and surgical products. Founded in 1985 with its headquarters in Marlborough, Massachusetts, Hologic operates across four distinct segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Its commitment to innovation and improving patient outcomes positions Hologic as a leader in the healthcare industry, ensuring it meets the diverse needs of healthcare providers and patients alike.
Products and Services
- Aptima Molecular Diagnostic Assays: These assays are designed to detect infectious microorganisms, playing a crucial role in the diagnosis and management of infectious diseases.
- Aptima Viral Load Assays: Specifies viral load measurements for Hepatitis B, Hepatitis C, HIV, and human cytomegalovirus, critical for monitoring and managing these infections.
- Aptima Bacterial Vaginosis and Candida Vaginitis Assays: Offer diagnosis solutions for vaginitis, improving patient care through accurate detection.
- Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 Assays: Enable the detection of SARS-CoV-2, the virus responsible for COVID-19, showcasing Hologic's capacity to respond to emergent health threats.
- ThinPrep System: Provides cytology applications, enhancing the accuracy of Pap tests for detecting cervical cancer at early stages.
- Rapid Fetal Fibronectin Test: Aids in assessing the risk of pre-term birth, offering critical information to healthcare providers for managing pregnancies.
- 3D Digital Mammography Systems: Revolutionizes breast cancer detection with advanced imaging technology, improving the early diagnosis of breast cancer.
- MyoSure Hysteroscopic Tissue Removal System: Allows for the minimally invasive removal of fibroids and polyps in the uterus, contributing to enhanced patient comfort and recovery.
- NovaSure Endometrial Ablation System: Provides treatment for abnormal uterine bleeding, offering an effective alternative to more invasive surgical procedures.
- Fluent Fluid Management System: Delivers liquid distention during hysteroscopic procedures, ensuring operational efficiency and safety.
- Acessa ProVu System: A minimally invasive solution for treating fibroids, demonstrating Hologic’s commitment to innovative treatment options.
- CoolSeal Portfolio: Features bipolar vessel sealing devices designed for surgical efficiency and patient safety during procedures.
- Horizon DXA: This dual-energy X-ray absorptiometry system is used for assessing bone density, aiding in the detection and treatment of osteoporosis.
- Fluoroscan Insight FD Mini C-arm: A compact imaging solution for orthopedic surgical procedures, enhancing the visualization needed for minimally invasive interventions.
Contact Information
Address: 250 Campus Drive
Phone: 508 263 2900
Website: https://www.hologic.com
2025 © Marketlog. All Rights Reserved.
